↓ Skip to main content

Case Report: Re-Sensitization to Gefitinib in Lung Adenocarcinoma Harboring EGFR Mutation and High PD-L1 Expression After Immunotherapy Resistance, Which Finally Transform Into Small Cell Carcinoma

Overview of attention for article published in Frontiers in oncology, June 2021
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Good Attention Score compared to outputs of the same age and source (74th percentile)

Mentioned by

twitter
3 X users

Citations

dimensions_citation
3 Dimensions

Readers on

mendeley
12 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Case Report: Re-Sensitization to Gefitinib in Lung Adenocarcinoma Harboring EGFR Mutation and High PD-L1 Expression After Immunotherapy Resistance, Which Finally Transform Into Small Cell Carcinoma
Published in
Frontiers in oncology, June 2021
DOI 10.3389/fonc.2021.661034
Pubmed ID
Authors

Xiaoqian Zhai, Jiewei Liu, Zuoyu Liang, Zhixi Li, Yanyang Liu, Lin Huang, Weiya Wang, Feng Luo

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 12 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 12 100%

Demographic breakdown

Readers by professional status Count As %
Other 3 25%
Student > Postgraduate 2 17%
Researcher 2 17%
Student > Ph. D. Student 1 8%
Student > Doctoral Student 1 8%
Other 2 17%
Unknown 1 8%
Readers by discipline Count As %
Medicine and Dentistry 4 33%
Nursing and Health Professions 2 17%
Pharmacology, Toxicology and Pharmaceutical Science 1 8%
Immunology and Microbiology 1 8%
Design 1 8%
Other 0 0%
Unknown 3 25%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 August 2021.
All research outputs
#16,059,145
of 25,392,582 outputs
Outputs from Frontiers in oncology
#5,644
of 22,433 outputs
Outputs of similar age
#243,333
of 455,417 outputs
Outputs of similar age from Frontiers in oncology
#321
of 1,443 outputs
Altmetric has tracked 25,392,582 research outputs across all sources so far. This one is in the 34th percentile – i.e., 34% of other outputs scored the same or lower than it.
So far Altmetric has tracked 22,433 research outputs from this source. They receive a mean Attention Score of 3.0. This one has gotten more attention than average, scoring higher than 71% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 455,417 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 43rd percentile – i.e., 43% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1,443 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.